135 Papers
367 Citations
Changli Wang is an academic researcher from Tianjin Medical University Cancer Institute and Hospital. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 23, co-authored 105 publications.
Chat about Author
Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Patrick M. Forde,Jonathan Spicer,Shun Lu,Mariano Provencio,Tetsuya Mitsudomi,Mark M. Awad,Enriqueta Felip,Stephen R. Broderick,Julie R. Brahmer,J. Swanson,Keith M. Kerr,Changli Wang,Tudor Ciuleanu,Gene Brian Saylors,Fumihiro Tanaka,Hiroyuki Ito,Keke Chen,Moishe Liberman,Everett E. Vokes,Janis M. Taube,C. Dorange,Junliang Cai,Joseph Fiore,Anthony Jarkowski,David Balli,Mark Sausen,Dimple Pandya,Christophe Y Calvet,Nicolas Girard +28 more
TL;DR: In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone.
910
Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Ji Feng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jian Wang,Songwen Zhou,Shengxiang Ren,Shaoyong Lu,Lin Zhang,Chengping Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +21 more
TL;DR: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutation-positive advanced non-small-cell lung cancer patients, suggesting that erlotinib should be considered standard first-line treatment of EGfr mutant patients and EGFR -TKI treatment following first- line therapy also brings significant benefits to those patients.
460
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial
Dongsheng Yue,Shidong Xu,Qun Wang,Xiaofei Li,Yi Shen,Heng Zhao,Chun Chen,Weimin Mao,Wei Liu,Junfeng Liu,Lanjun Zhang,Haitao Ma,Qiang Li,Yue Yang,Yongyu Liu,Haiquan Chen,Changli Wang +16 more
TL;DR: It is suggested that tyrosine kinase inhibitors could have a potentially important role as adjuvant therapy in EGFR mutation-positive stage IIIA NSCLC, however, this trial was a phase 2 study and Mature overall survival data are also needed.
277
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
Wen-Zhao Zhong,Ke-Neng Chen,Chun Chen,Chun-Dong Gu,Jun Wang,Xue-Ning Yang,Weimin Mao,Qun Wang,Gui-bin Qiao,Ying Cheng,Lin Xu,Changli Wang,Mingwei Chen,Xiaozheng Kang,Wanpu Yan,Hong-Hong Yan,Ri-Qiang Liao,Jin-Ji Yang,Xu-Chao Zhang,Qing Zhou,Yi-Long Wu +20 more
TL;DR: The primary end point of ORR with 42 days of neoadjuvant erlotinib was not met, but the secondary end point PFS was significantly improved, which reflected those most commonly seen with the two treatments.
236